Bachleda Mark Insider Trades

Insider Trading History

Track insider trading activity for Bachleda Mark. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Lyell Immunopharma
Lyell Immunopharma LYEL
Director
Holding Value $124k 9,250 shares
Last Trade
Jun 10, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$122k 9,250 shares
$13.22
$13.40
Lyell Immunopharma
Lyell Immunopharma LYEL
Director
Holding Value $174k 13,000 shares
Last Trade
Jun 09, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$162k 13,000 shares
$12.47
$13.40
Galera Therapeutics
Galera Therapeutics GRTX
Chief Commercial Officer
Holding Value $182k 11,000 shares
Last Trade
Mar 16, 2023 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$24.8k 11,000 shares
$2.25
$16.56
Galera Therapeutics
Galera Therapeutics GRTX
Chief Commercial Officer
Holding Value $2.24M 135,000 shares
Last Trade
Feb 25, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$240k 135,000 shares
$1.78
$16.56
Galera Therapeutics
Galera Therapeutics GRTX
Chief Commercial Officer
Holding Value $1.24M 75,000 shares
Last Trade
Feb 28, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$168k 75,000 shares
$2.24
$16.56
Galera Therapeutics
Galera Therapeutics GRTX
Chief Commercial Officer
Holding Value $3.31M 200,000 shares
Last Trade
Oct 08, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.57M 200,000 shares
$7.84
$16.56

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up